Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
This session of the ISGIO 2025 meeting focused on updates in the management of hepatobiliary cancers. This included a presentation on the role of liver transplant in the management of cholangiocarcinoma and another on the use of HER2-directed therapies in advanced biliary tract cancers. The latter portion of the session was dedicated to advances in immunotherapy for intermediate- and advanced-stage hepatocellular cancer, framed by presentation and discussion of a patient case.
Registration is
also now open for ISGIO 2026, taking place October 2-3, 2026, in Ft
Lauderdale, Florida. Click here to learn more.
Target Audience
This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in GI oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate biomarker testing results to individualize treatment selection for patients with GI cancers
- Evaluate the latest efficacy and safety data for newly approved agents, novel combinations, and novel agents to consider their potential impact on evolving treatment paradigms in GI cancers
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here